Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb 6;60(1):11.
doi: 10.1007/s44313-025-00056-8.

Is t(11;14) in newly diagnosed multiple myeloma a favorable outcome in the novel agent era?

Ye Li  1 , Jingjing Deng  2 , Yuan Jian  2 , Zhiyao Zhang  2 , Wenming Chen  3
Affiliations

Is t(11;14) in newly diagnosed multiple myeloma a favorable outcome in the novel agent era?

Ye Li et al. Blood Res. .

Abstract

Background: t(11;14) is considered a standard risk factor in multiple myeloma (MM). However, recent studies suggested that its impact in the context of novel agents remained controversial.

Methods: This retrospective analysis examined the clinical profiles of 375 newly diagnosed patients with MM and compared the outcomes between those with t(11;14) and those with normal cytogenetics.

Results: The median progression-free survival (PFS) of the 84 patients with t(11;14) was 36 months (95% confidence interval (CI), 23.5-48.5), which was significantly shorter than the median PFS of 65 months (95% CI, 23.0-107.0) for the 59 patients with normal cytogenetics (p = 0.011). Median overall survival (OS) was not reached in either group (p = 0.977). When combined with 1q21 + , t(11;14) showed a trend toward poorer PFS (median PFS: 36 vs. 65 months; p = 0.130). In the presence of high-risk cytogenetics (HRCAs), t(11;14) was associated with a worse PFS (median PFS: 9 vs. 38 months, p = 0.015) and a trend toward shorter OS (median OS: 33 vs. 49 months, p = 0.096). Multivariate analysis indicated that t(11;14) was a poor prognostic factor for PFS. 1q21 + was a detrimental prognostic factor, particularly in the t(11;14) group. Autologous stem cell transplantation (ASCT) may be a beneficial treatment option for patients with t(11;14).

Conclusion: In this study, patients with MM with t(11;14) demonstrated poorer PFS than those with normal cytogenetics. Further investigations are required to evaluate the impact of t(11;14) in patients newly diagnosed with MM in the era of novel agents.

Keywords: 1q21 +; Del(17p); High-risk cytogenetic abnormalities; Multiple Myeloma; T(11;14).

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: This study was approved by the Medical Ethics Committee of Beijing Chaoyang Hospital. We followed patients through an electronic medical record system without disturbing them in any way or interfering with their treatment. Informed consent was not required because the data were anonymized. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Kaplan–Meier analysis of 84 patients with t (11;14) and 59 normal cytogenetics cases for PFS (A) and OS (B)
Fig. 2
Fig. 2
Kaplan–Meier analysis of t(11;14) + 1q21 + and non-t(11;14) + 1q21 + groups for PFS (A) and OS (B); analysis of t(11;14) + HRCAs and non-t(11;14) + HRCAs groups for PFS (C) and OS (D)
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97:1086–1107.10.1002/ajh.26590. - PMC - PubMed
    1. Terragna C, Poletti A, Solli V, et al. Multi-dimensional scaling techniques unveiled gain1q&loss13q co-occurrence in Multiple Myeloma patients with specific genomic, transcriptional and adverse clinical features. Nat Commun. 2024;15:1551.10.1038/s41467-024-45000-z. - PMC - PubMed
    1. Clarke SE, Fuller KA, Erber WN. Chromosomal defects in multiple myeloma. Blood Rev. 2024;64:101168.10.1016/j.blre.2024.101168. - PubMed
    1. Munshi NC, Anderson KC, Bergsagel PL, et al. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood. 2011;117:4696–4700.10.1182/blood-2010-10-300970. - PMC - PubMed
    1. Dispenzieri A, Rajkumar SV, Gertz MA, et al. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc. 2007;82:323–341.10.4065/82.3.323. - PubMed

LinkOut - more resources